Quest Diagnostics Partners with Octave Bioscience to Expand Access to MS Disease Activity Test

Reuters12-01

Quest Diagnostics Partners with Octave Bioscience to Expand Access to MS Disease Activity Test

Quest Diagnostics Incorporated has announced a strategic collaboration with Octave Bioscience to expand patient access to the Octave® Multiple Sclerosis Disease Activity $(MSDA)$ Test across the United States. Through this partnership, patients can utilize Quest's network of approximately 7,000 patient service centers for specimen collection, making the MSDA Test more widely available. The agreement also provides Quest with the first opportunity to offer specimen collection services for future tests developed by Octave for multiple sclerosis and Parkinson's disease. This collaboration aims to enhance the standard of care for neurodegenerative diseases by providing easier access to advanced, blood-based diagnostic tools.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201400583) on December 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588778502?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-01 21:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588778502","market":"nz","top_or_hot":-1,"title":"Quest Diagnostics Partners with Octave Bioscience to Expand Access to MS Disease Activity Test","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quest Diagnostics Partners with Octave Bioscience to Expand Access to MS Disease Activity Test\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quest Diagnostics Incorporated has announced a strategic collaboration with Octave Bioscience to expand patient access to the Octave® Multiple Sclerosis Disease Activity <a href=\"https://laohu8.com/S/MSDA\">$(MSDA)$</a> Test across the United States. Through this partnership, patients can utilize Quest's network of approximately 7,000 patient service centers for specimen collection, making the MSDA Test more widely available. The agreement also provides Quest with the first opportunity to offer specimen collection services for future tests developed by Octave for multiple sclerosis and Parkinson's disease. This collaboration aims to enhance the standard of care for neurodegenerative diseases by providing easier access to advanced, blood-based diagnostic tools.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201400583) on December 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quest Diagnostics Partners with Octave Bioscience to Expand Access to MS Disease Activity Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuest Diagnostics Partners with Octave Bioscience to Expand Access to MS Disease Activity Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-01 21:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quest Diagnostics Partners with Octave Bioscience to Expand Access to MS Disease Activity Test\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quest Diagnostics Incorporated has announced a strategic collaboration with Octave Bioscience to expand patient access to the Octave® Multiple Sclerosis Disease Activity <a href=\"https://laohu8.com/S/MSDA\">$(MSDA)$</a> Test across the United States. Through this partnership, patients can utilize Quest's network of approximately 7,000 patient service centers for specimen collection, making the MSDA Test more widely available. The agreement also provides Quest with the first opportunity to offer specimen collection services for future tests developed by Octave for multiple sclerosis and Parkinson's disease. This collaboration aims to enhance the standard of care for neurodegenerative diseases by providing easier access to advanced, blood-based diagnostic tools.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201400583) on December 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2506951958.HKD","symbol_name":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL7dh9l5:1","article_id":"2588778502","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588778502","pubTimestamp":1764595854,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Quest Diagnostics Incorporated has announced a strategic collaboration with Octave Bioscience to expand patient access to the Octave Multiple Sclerosis Disease Activity  Test across the United States. Through this partnership, patients can utilize Quest's network of approximately 7,000 patient service centers for specimen collection, making the MSDA Test more widely available. The agreement also provides Quest with the first opportunity to offer specimen collection services for future tests developed by Octave for multiple sclerosis and Parkinson's disease. This collaboration aims to enhance the standard of care for neurodegenerative diseases by providing easier access to advanced, blood-based diagnostic tools.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, invest","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","DGX":"奎斯特诊疗","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","BK4583":"猴痘概念","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","BK4567":"ESG概念","BK4196":"保健护理服务","BK4588":"碎股","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","BK4585":"ETF&股票定投概念","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC"},"translate_title":"Quest Diagnostics与Octave Bioscience合作扩大MS疾病活性测试的范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DGX":0.9},"content_text":"Quest Diagnostics Partners with Octave Bioscience to Expand Access to MS Disease Activity Test\n    \n\n        Quest Diagnostics Incorporated has announced a strategic collaboration with Octave Bioscience to expand patient access to the Octave® Multiple Sclerosis Disease Activity $(MSDA)$ Test across the United States. Through this partnership, patients can utilize Quest's network of approximately 7,000 patient service centers for specimen collection, making the MSDA Test more widely available. The agreement also provides Quest with the first opportunity to offer specimen collection services for future tests developed by Octave for multiple sclerosis and Parkinson's disease. This collaboration aims to enhance the standard of care for neurodegenerative diseases by providing easier access to advanced, blood-based diagnostic tools.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20251201400583) on December 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588778502","isCrawlerRequest":true}